12 Biotechs With Binary Events Coming This Year

RBC Capital analyst Adnan Butt recently named 12 biotech stocks with major binary events expected in 2016.

Here’s a breakdown of the full list.

  • Aerie Pharmaceuticals Inc AERI: Phase 3 data for Rhopressa and Roclatan
  • Aptose Biosciences Inc APTO: Phase 1 data for APTO-253
  • ArQule, Inc. ARQL: Phase 3 interim for tivantinib and Phase 1 data/update for ARQ-092 in Proteus syndrome
  • Curis, Inc. CRIS: Phase 1 update from CUDC-907, CA-170 and potential additional programs
  • Endocyte, Inc. ECTY: Phase 1 data for EC1456 and EC1169
  • Intra-Cellular Therapies Inc ITCI: Phase 3 data for ITI-007
  • The Medicines Company MDCO: Phase 2 data for MDCO-216 and ALN-PCSsc and Phase 3 data for Caravance
  • Oculus Innovative Sciences, Inc. OCLS: Phase 3 data for OTX-DP, regulatory clarity on OTX-TP development and a POC study or partnership for anti-VEGF IHD
  • SCYNEXIS Inc SCYX: Phase 1 and Phase 2 data for i.v. and oral SCY-078
  • Steadymed Ltd STDY: Acceptance of Trevyent for review
  • Synthetic Biologics Inc SYN: Phase 2 data from SYN-010 and possibly SYN-004
  • XOMA Corp XOMA: Phase2/proof-of-concept data from XOMA 358 and potentially Phase 3 from gevokizuamb

Related Link: 2 Fast-Growing Marketing Startups You've Never Heard Of

Butt sees “significant upside” for most of these companies in the case of a positive result, but adds that the sell-off following negative results would most likely be temporary in the majority of cases.

Disclosure: the author holds no position in the stocks mentioned.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsPreviewsFDAAnalyst RatingsTrading IdeasGeneralBiotechbiotech catalysts
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!